West Pharmaceutical Services, Inc. (WST)
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, decline across its Generics and Biologics business units is concerning.
West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Q3 2024 Results Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants John Sweeney - Vice President, Investor Relations Eric Green - Chairman, President and Chief Executive Officer Bernard Birkett - Senior Vice President, Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Lawrence Solow - CJS Securities Michael Ryskin - BofA Global Research David Windley - Jefferies Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank Thomas DeBourcy - Nephron Research Operator Good day and thank you for standing by. Welcome to the Q3 2024 West Pharmaceutical Services Earnings Conference Call.
West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend
On Thursday, West Pharmaceutical Services, Inc. WST reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50.
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $2.16 per share a year ago.
West Pharmaceutical raises annual profit forecast on demand for medical supplies
West Pharmaceutical Services raised its annual profit forecast on Thursday, after beating Wall Street estimates for quarterly revenue and profit, banking on rising demand for cartridges and syringes used to manufacture injectable therapies.
What's in Store for West Pharmaceutical in Q3 Earnings?
WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.
Earnings Preview: West Pharmaceutical Services (WST) Q3 Earnings Expected to Decline
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
West Pharmaceutical Q2'24 results missed expectations, with lower revenues and EPS missing guidance, impacted by destocking and poor sales in various segments. Management remains optimistic for the back half of the year, with capital investments to support growth, but cash flow concerns and high valuation pose risks. Despite the recent drop in WST share price, the company's high valuation and uncertain cash flow outlook make it unattractive for investment at this time.
West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Miss Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.52 per share, missing the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.11 per share a year ago.
